Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry
Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse. Early detection of ibrutinib resistance is an important issue, therefore we aimed to...
Elmentve itt :
Szerzők: | |
---|---|
Dokumentumtípus: | Cikk |
Megjelent: |
2022
|
Sorozat: | PATHOLOGY AND ONCOLOGY RESEARCH
28 |
Tárgyszavak: | |
doi: | 10.3389/pore.2022.1610659 |
mtmt: | 33104808 |
Online Access: | http://publicatio.bibl.u-szeged.hu/25676 |
Tartalmi kivonat: | Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse. Early detection of ibrutinib resistance is an important issue, therefore we aimed to find phenotypic markers on CLL cells the expression of which may correlate with the appearance of ibrutinib resistance. |
---|---|
Terjedelem/Fizikai jellemzők: | 7 |
ISSN: | 1219-4956 |